Participant flow

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer · Source last updated 2016-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) ("Concurrent Phase") for three 21-day cycles, followed by a 3-5 week "Recovery Period," then treated with consolidation chemotherapy with pemetrexed ("Consolidation Phase") for up to four 21-day cycles Concurrent Phase: Pemetrexed: 500 milligrams per meter squared (mg/m\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \[Gy\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions. Consolidation Phase: Pemetrexed: 500 mg/m\^2, IV on Day 1 of each 21-day cycle up to 4 cycles

   id

   FG000

   title

   Arm A: Pemetrexed + Cisplatin and TRT

2. description

   Participants were treated with Etoposide plus Cisplatin and concurrent TRT ("Concurrent Phase") for two 28-day cycles, followed by a 3-5 week "Recovery Period," then received consolidation treatment with cytotoxic chemotherapy of choice ("Consolidation Phase") for up to 2 cycles Concurrent Phase: Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\^2, IV on Days1, 8, 29, and 36 Consolidation Phase options: Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22

   id

   FG001

   title

   Arm B: Etoposide + Cisplatin and TRT

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         124

      2. group Id

         FG001

         num Subjects

         117

      type

      Participants censored (no death events)

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         301

      2. group Id

         FG001

         num Subjects

         297

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         283

      2. group Id

         FG001

         num Subjects

         272

      type

      Received at Least One Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         229

      2. group Id

         FG001

         num Subjects

         202

      type

      Entered Consolidation Phase

   4. achievements

      1. comment

         Study completion includes death due to any cause

         group Id

         FG000

         num Subjects

         177

      2. comment

         Study completion includes death due to any cause.

         group Id

         FG001

         num Subjects

         180

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         124

      2. group Id

         FG001

         num Subjects

         117

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice